Medications

Nasal spray approved for treating suicidal people

Johnson & Johnson's Spravato has been approved as the first antidepressant for actively suicidal people, as doctors are becoming increasingly concerned about COVID-19's effect on the mental health of Americans.

Psychology & Psychiatry

Hospital study examines the cost-effectiveness of esketamine

A paper authored by researchers from McLean Hospital has determined that esketamine, a nasal spray to treat severe depression, is currently too expensive for widespread use. Titled "Cost-Effectiveness of Esketamine Nasal ...

Psychology & Psychiatry

New study shows how ketamine combats depression

In low doses, the anaesthetic drug ketamine has been shown to have a rapid effect on difficult-to-treat depression. Researchers at Karolinska Institutet report that they have identified a key target for the drug: specific ...

Psychology & Psychiatry

Researchers ID symptom-specific targets for treatment of depression

Depression is the leading cause of disability worldwide, striking as many as one in four women and one in eight men in their lifetimes. While more than 17 million adults in the United States struggled with the disease in ...

page 1 from 19